Loading publications…
The last 5 uploaded publications
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul, Éveline Boucher, Masatoshi Kudo, Charissa Chang, Yoon‐Koo Kang, Éric Assenat, Ho-Yeong Lim, Valérie Boige, Philippe Mathurin, Lætitia Fartoux, Deng‐Yn Lin, Jordi Bruix, Ronnie T.P. Poon, Morris Sherman, Jean–Frédéric Blanc, Richard S. Finn, Won Young Tak, Yee Chao, Rana Ezzeddine, David Liu, Ian Walters, Joong‐Won Park (2013). Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. Journal of Clinical Oncology, 31(28), pp. 3509-3516, DOI: 10.1200/jco.2012.47.3009.
Article145 days agoObjective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
Riccardo Lencioni, Robert Montal, Ferrán Torres, Joong‐Won Park, Thomas Decaens, Jean‐Luc Raoul, Masatoshi Kudo, Charissa Chang, José Ríos, Valérie Boige, Éric Assenat, Yoon‐Koo Kang, Ho-Yeong Lim, Ian Walters, Josep M. Llovet (2017). Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. Journal of Hepatology, 66(6), pp. 1166-1172, DOI: 10.1016/j.jhep.2017.01.012.
Article145 days ago1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY
Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul, Éveline Boucher, Masatoshi Kudo, Cheng‐Chen Chang, Yang Kang, Éric Assenat, Ho-Yeong Lim, Valérie Boige, Philippe Mathurin, Lætitia Fartoux, Derek Lin, Jordi Bruix, Rtp Poon, Morris Sherman, J.-F. Blanc, Richard S. Finn, Won Young Tak, You‐Chen Chao, Rana Ezzeddine, D. Liu, Ian Walters, J.-W. Park (2012). 1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY. Journal of Hepatology, 56, pp. S549-S549, DOI: 10.1016/s0168-8278(12)61409-3.
Article145 days agoObjective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study.
Josep M. Llovet, Joong‐Won Park, Ferrán Torres, Thomas Decaens, Éveline Boucher, Jean‐Luc Raoul, Masatoshi Kudo, Charissa Chang, Valérie Boige, Éric Assenat, Yoon‐Koo Kang, Ho-Yeong Lim, Ian Walters, Riccardo Lencioni (2015). Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study.. Journal of Clinical Oncology, 33(15_suppl), pp. 4084-4084, DOI: 10.1200/jco.2015.33.15_suppl.4084.
Article145 days agoChemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Erika Vacchelli, Yuting Ma, Elisa Elena Baracco, Antonella Sistigu, David Enot, Federico Pietrocola, Heng Yang, Sandy Adjemian, Kariman Chaba, Michaëla Semeraro, Michele Signore, Adele De Ninno, Valeria Lucarini, Francesca Peschiaroli, Luca Businaro, Annamaria Gerardino, Gwenola Manic, Thomas Ulas, Patrick Günther, Joachim L. Schultze, Oliver Kepp, Gautier Stoll, Céline Lefèbvre, Claire Mulot, Francesca Castoldi, Sylvie Rusakiewicz, Sylvain Ladoire, Lionel Apétoh, José Manuel Bravo‐San Pedro, Monica Lucattelli, Cécile Delarasse, Valérie Boige, Michel Ducreux, Suzette Delaloge, Christophe Borg, Fabrice André, Giovanna Schiavoni, Ilio Vitale, Pierre Laurent‐Puig, Fabrizio Mattei, Laurence Zitvogel, Guido Guido Kroemer (2015). Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. , 350(6263), DOI: https://doi.org/10.1126/science.aad0779.
Article73 days ago